A. Gallus
Internal Medicine · 2006–2014
A researcher in the Science corpus: 10 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Internal Medicine — 78 citations into it
Whom A. Gallus trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from A. Gallus's perspective
Ordered by how strongly the researchers A. Gallus trusts endorse each paper. Same corpus, a different order for every researcher.
- The epidemiology of venous thromboembolism in the community. (Arteriosclerosis, Thrombosis and Vascular Biology)
- Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (New England Journal of Medicine)
- Dabigatran versus warfarin in the treatment of acute venous thromboembolism. (New England Journal of Medicine)
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
- Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. (Archives of Internal Medicine)
- Oral apixaban for the treatment of acute venous thromboembolism. (New England Journal of Medicine)
- Fibrinolysis for patients with intermediate-risk pulmonary embolism. (New England Journal of Medicine)
- Emergency hospitalizations for adverse drug events in older Americans. (New England Journal of Medicine)
- Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. (Archives of Internal Medicine)
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (New England Journal of Medicine)
Their papers
- Thrombosis: A Major Contributor to Global Disease Burden (2014) — 635 citations
- Apixaban for extended treatment of venous thromboembolism. (2013) — 1,268 citations
- Oral apixaban for the treatment of acute venous thromboembolism. (2013) — 2,195 citations
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) — 1,719 citations
- Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) — 1,405 citations
- Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. (2010) — 781 citations
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. (2010) — 796 citations
- Oral rivaroxaban for symptomatic venous thromboembolism. (2010) — 2,252 citations
- Apixaban or enoxaparin for thromboprophylaxis after knee replacement. (2009) — 726 citations
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial (2006) — 841 citations